Preliminary Results From IMVa??s Phase 2 Basket Trial Evaluating DPX-Survivac as a Combination Therapy in Patients with Advanced and Metastatic Solid Tumors to Be Presented at ESMO Congress 2019

23.09.2019, 14:05,
Business and Finance » Business and Finance. Main

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today announced that preliminary results from its ongoing Phase 2 basket trial, evaluating DPX-Survivac in combination with Mercka??s KeytrudaA® (pembrolizumab) and intermittent low dose cyclophosphamide (CPA) in patients with advanced and metastatic solid tumors, will be presented during the Immunotherapy of Cancer poster session at the European Society for Medical Oncology (ESMO) 2019 Congress, being held September 27 a?? October 1, 2019, in Barcelona, Spain.

Presentation Details

Poster Title: "Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumours (preliminary results)a??

Presenter: Henry J Conter, M.D., Medical Oncology Director, William Osler Cancer Centre

Date and Time: Sept. 30, 2019, 12:00-13:00 CEST a?? poster will be displayed all day

Abstract Number: 1208P

Session Title: Immunotherapy of Cancer

Poster Display: Session 3, Poster Area a?? Hall 4

» Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Head and Neck Squamous Cell Carcinoma at the 2019 ASCO Annual Meeting

» IMV Inc. Presents New Positive Data from Phase 2 Monotherapy Arm of Its Decide1 Trial in Advanced Ovarian Cancer and Continued Duration of Clinical Benefits to Patients with Progression Free Survival

» IMV to Provide Updated Clinical Data at 2019 ASCO Annual Meeting on Lead Candidate DPX-Survivac in Ovarian Cancer and Other Solid Tumors

» Generex Biotechnology Receives IND Approval from FDA for Phase II Combination Study using AE37 plus Keytruda® (pembrolizumab) for the Treatment of Triple Negative Breast Cancer

» Bristol-Myers Says Follow-up Data Of Opdivo With Yervoy Shows Promising Results